High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas

Douglas E. GladstoneThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USACorrespondence[email protected]

Javier Bolaños-MeadeThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Carol Ann HuffThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Marianna ZahurakDivision of Biostatistics, Johns Hopkins University, Baltimore, MD, USA

Ian FlinnTennessee Oncology, Nashville, TN, USA

Ivan BorrelloThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Leo LuznikThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Ephraim FuchsThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Yvette KasamonThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

William MatsuiThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Jonathan PowellThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Hyam LevitskyThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Robert A. BrodskyDivision of Hematology, Johns Hopkins University, Baltimore, MD, USA

Richard AmbinderThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Richard J. JonesThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Lode J. SwinnenThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

References